#United States #CardioFlux #Genetesis #Heart Health #Mason

Genetesis Unveils CardioFlux Membership Program

In a groundbreaking initiative, Genetesis, Inc., a prominent figure in the realm of magnetocardiography (MCG), has announced the launch of its innovative CardioFlux Membership program. This program aims to revolutionize the way individuals monitor their heart health and takes a significant step toward preventing heart disease, which has long been the leading cause of death in the United States.

A New Frontier in Preventive Cardiac Care

The CardioFlux Membership program is designed to provide members with a user-friendly and effective means to regularly assess their heart's health. Enrolled members can schedule visits to tailored CardioFlux Imaging Institutes (CIIs), where they will undergo a quick heart scan to evaluate their myocardial fitness over time. This continuous monitoring is represented through a unique metric termed the CardioFlux Score.

The official debut of the membership program is complemented by the grand opening of the first CardioFlux Imaging Institute located in Mason, Ohio. This site has been strategically positioned in one of the most vibrant and rapidly expanding areas near Cincinnati, enabling Genetesis to extend its innovative services across the country.

Peeyush Shrivastava, co-founder and CEO of Genetesis, shared his thoughts on the company's vision: "From our inception, our goal was to leverage technology not only to detect diseases but to prevent them altogether. This launch signifies our commitment to changing the narrative around cardiac care, targeting heart disease proactively rather than reactively."

Introducing the CardioFlux Score

A key feature of the CardioFlux Membership is the CardioFlux Score, which serves as a valuable indicator of myocardial fitness—essentially, the heart muscle's health. By analyzing 14 distinct biomarkers that represent the heart’s electrical activity, the score offers insights comparable to those of healthy individuals without symptoms.

This score is sensitive to various lifestyle factors and health changes, such as diet, medication, and even age, allowing members to track how their heart health evolves.

Understanding that traditional imaging methods can be invasive and uncomfortable, the CardioFlux MCG device provides a quiet, non-invasive assessment that requires just 90 seconds. Importantly, it eliminates exposure to ionizing radiation and does not necessitate medications or physical exertion.

Currently, this technology has received both FDA clearance and a medical device license from Health Canada, with ongoing clinical trials at notable institutions including the Cleveland Clinic and Mayo Clinic. These studies focus on the combined diagnostic and preventive capabilities of the MCG technology.

Accessing the CardioFlux Membership

Genetesis offers three distinct membership plans to cater to varying needs:

• - Starter: $349 for a limited number of CardioFlux Scores per year
• - Core: $499 for a mid-level package
• - Pro: $999, designed for those seeking extensive monitoring

Each plan includes a complimentary Score Consult with a certified physician, and members can access and share their results through a personalized online platform.

What sets the CardioFlux Membership apart is its accessibility; no physician referral is required, allowing anyone to participate and prioritize their heart health without obstruction.

Dr. Robert Takla, Chief Medical Officer at Genetesis, emphasizes the need for a transformative approach: "Heart disease has stubbornly remained the leading cause of death for over a hundred years. Our initiative seeks to empower individuals to monitor their heart health proactively, akin to how we've tackled cancer over the past twenty years."

For those interested in understanding more about their heart health through this innovative initiative, additional information can be found on the CardioFlux website.

About Genetesis

Founded in 2013 and based just north of Cincinnati, Ohio, Genetesis has been dedicated to transforming decades of research into actionable health insights using magnetocardiography technology. By taking a proactive stance on heart health, Genetesis seeks to pave a path toward a world free from heart disease.

For requesting further details on the CardioFlux program or to become a member, visit CardioFlux.